Founded in 2014, 3D Medicines are a bio-pharmaceutical company focusing on the research and development of oncology therapies for cancer patients, especially those who require long-term care. Our core business model is to develop and commercialize oncology products and drug candidates through a combination of co-development, in-licensing and in-house discovery. As of the Latest Practicable Date, we have built a pipeline consisting of one Core Product and 11 drug candidates, among which, the Core Product envafolimab (brand name: ENWEIDA, 恩維達®), as our backbone, was approved in November 2021 and commercialized in December 2021, and seven other drug candidates are in clinical stage (including those drug candidates for which we have initiated clinical trials or have received IND approvals and are preparing for initiation of clinical trials).


Share Price

IR Calendar